Filtered By:
Drug: Rituxan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 5482 results found since Jan 2013.
Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital
CONCLUSION: CRT may be omitted in patients with a negative end of treatment PET scans; however, careful observation may also obviate the need for CRT in PET positive patients.PMID:37734988 | DOI:10.1016/j.clml.2023.08.021
Source: Clinical Lymphoma and Myeloma - September 21, 2023 Category: Cancer & Oncology Authors: Su Li Bhupinder Sharma Siraj Yusuf Vasiliki Michalarea Mary Gleeson Laura Hickmott Andrew Wotherspoon Ayoma D Attygalle Katherine Vroobel Simon O'Connor Yong Du Andrea Kuhnl Sunil Iyengar Dima El-Sharkawi Ian Chau David Cunningham Source Type: research
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.ABSTRACTHepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving chemotherapy, especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation. Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver. The expression of these silent genomes is controlled by the immune system. Suppression or ablation of immune cells, most imp...
Source: World Journal of Gastroenterology : WJG - September 21, 2023 Category: Gastroenterology Authors: Joyce Wing Yan Mak Alvin Wing Hin Law Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law Source Type: research
Nursing Alchemy: Transforming R-CHOP Information Into Essentials
Clin J Oncol Nurs. 2023 Sep 15;27(5):553-564. doi: 10.1188/23.CJON.553-564.ABSTRACTA combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a first-line combination chemotherapy regimen for diffuse large B-cell lymphoma that has many nursing implications. Understand.PMID:37729458 | DOI:10.1188/23.CJON.553-564
Source: Clinical Journal of Oncology Nursing - September 20, 2023 Category: Nursing Authors: Alexandra K Sakowski Puja R Patel Source Type: research
General recommendations for the management of glomerular diseases-2023
Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):696-704. doi: 10.1007/s00508-023-02265-6. Epub 2023 Sep 20.ABSTRACTGlomerular diseases are associated with extrarenal complications, such as thromboembolism, cardiovascular events and particularly infections. A thorough knowledge of the various immunosuppressants and their associated toxicity profile is therefore of great importance. While nephrologists usually have extensive experience with calcineurin inhibitors and antimetabolites, two other compounds (rituximab, in severe cases cyclophosphamide) are used comparatively infrequently and will be discussed in more detail. Moreove...
Source: Wiener Klinische Wochenschrift - September 20, 2023 Category: General Medicine Authors: Martin Windpessl Philipp Gauckler Emanuel Zitt Karl Lhotta Cihan Ay Kathrin Eller Balazs Odler Irmgard Neumann Michael Rudnicki Andreas Kronbichler Marcus D S äemann Source Type: research
Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury
Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):688-695. doi: 10.1007/s00508-023-02264-7. Epub 2023 Sep 20.ABSTRACTMembranoproliferative glomerulonephritis (MPGN) represents a heterogeneous group of diseases. The common feature of a membranoproliferative lesion pattern in the kidney biopsy can either be idiopathic/primary or-much more frequently-have a secondary cause. The historical classification into MPGN types I to III has largely been abandoned and replaced in recent years by a pathogenesis-oriented classification. A MPGN with C1q, C3 and/or C4 deposits on light microscopy is referred to as immune complex GN (IC-GN), whil...
Source: Wiener Klinische Wochenschrift - September 20, 2023 Category: General Medicine Authors: Michael Rudnicki Martin Windpessl Kathrin Eller Balazs Odler Philipp Gauckler Irmgard Neumann Emanuel Zitt Heinz Regele Andreas Kronbichler Karl Lhotta Marcus D S äemann Source Type: research
Diagnosis and therapy of membranous nephropathy-2023
Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):648-655. doi: 10.1007/s00508-023-02261-w. Epub 2023 Sep 20.ABSTRACTMembranous nephropathy (MN) is an immune-complex glomerulonephritis and is one of the most common causes of nephrotic syndrome in adults and is also one of the autoimmune kidney diseases with the highest rate of spontaneous remission. The most common autoantigen (> 70% of cases) is directed against the phospholipase A2 receptor (PLA2-R) and, with its detection and clinical course, allows for excellent diagnostics as well as optimal therapy monitoring. Other autoantigens are constantly being published and will e...
Source: Wiener Klinische Wochenschrift - September 20, 2023 Category: General Medicine Authors: Marcus D S äemann Balazs Odler Martin Windpessl Heinz Regele Kathrin Eller Irmgard Neumann Michael Rudnicki Philipp Gauckler Andreas Kronbichler Maarten Knechtelsdorfer Source Type: research
Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis
CONCLUSION: Acthar Gel is associated with reductions in corticosteroid use compared to alternatives. Better adherence is associated with greater reduction in corticosteroid exposure. Key Summary Points.PMID:37728695 | DOI:10.1007/s12325-023-02630-x
Source: Adv Data - September 20, 2023 Category: Epidemiology Authors: Kyle Hayes John Niewoehner J Bradford Rice Nathaniel Downes Ella Hagopian Izzy Ma George J Wan Source Type: research
Synchronous rectal adenocarcinoma and intestinal mantle cell lymphoma: A case report
CONCLUSION: Synchronous rectal adenocarcinoma and intestinal MCL presenting as multiple lymphomatous polyposis are extremely rare. MCL is often discovered fortuitously when rectal cancer is diagnosed. The coexistence of these tumors poses treatment challenges.PMID:37727717 | PMC:PMC10506007 | DOI:10.12998/wjcc.v11.i24.5772
Source: Clinical Colorectal Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Kim-Van Vu Nguyen-Van Trong Nguyen-Thi Khuyen Do Huyen Nga Hoang Anh Nguyen Tien Trung Pham Trung Thong Nguyen Minh Duc Source Type: research
General recommendations for the management of glomerular diseases-2023
Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):696-704. doi: 10.1007/s00508-023-02265-6. Epub 2023 Sep 20.ABSTRACTGlomerular diseases are associated with extrarenal complications, such as thromboembolism, cardiovascular events and particularly infections. A thorough knowledge of the various immunosuppressants and their associated toxicity profile is therefore of great importance. While nephrologists usually have extensive experience with calcineurin inhibitors and antimetabolites, two other compounds (rituximab, in severe cases cyclophosphamide) are used comparatively infrequently and will be discussed in more detail. Moreove...
Source: Hamostaseologie - September 20, 2023 Category: Hematology Authors: Martin Windpessl Philipp Gauckler Emanuel Zitt Karl Lhotta Cihan Ay Kathrin Eller Balazs Odler Irmgard Neumann Michael Rudnicki Andreas Kronbichler Marcus D S äemann Source Type: research
Updates in the Management of Primary Mediastinal B Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 Aug 21:S2152-2650(23)00274-4. doi: 10.1016/j.clml.2023.08.014. Online ahead of print.ABSTRACTPrimary mediastinal B cell lymphoma (PMBCL) is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose-adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under i...
Source: Clinical Lymphoma and Myeloma - September 18, 2023 Category: Cancer & Oncology Authors: Charbel Soueidy Hampig Raphael Kourie Source Type: research
Significant CA 19-9 Elevation in IgG4-Related Autoimmune Pancreatitis - A Diagnostic Dilemma
We describe the case of a 65-year-old male with history of IgG4-RD, presenting with jaundice and abdominal pain. He was found to have a pancreatic mass with significantly elevated IgG4 162 (2-96 mg/dL and CA19-9 levels 2830 (0-35 U/ml). Patient underwent ERCP and biopsy, which ruled out pancreatic cancer and cholangiocarcinoma. He was diagnosed with IgG4-RD autoimmune pancreatitis (AIP) and sclerosing cholangitis. Treatment with steroids and rituximab resulted in significant improvement in the bilirubin and a dramatic decrease in CA19-9 levels.PMID:37714269 | DOI:10.1016/j.amjms.2023.09.016
Source: The American Journal of the Medical Sciences - September 15, 2023 Category: General Medicine Authors: Larabe Farrukh Muhammad Farhan Akhtar Hafiza Hareem Waqar Ruben Peredo-Wende Source Type: research
Clinical improvement in early onset interstitial lung disease using rituximab in children with anti-MDA5 positive juvenile dermatomyositis
CONCLUSION: This is the first study to examine the use of RTX in children with JDM and anti-MDA5 antibodies, with notable improvements ILD, cutaneous and musculoskeletal manifestations. Further studies are needed to better understand the efficacy of RTX on JDM disease related complications.PMID:37714547 | DOI:10.3899/jrheum.2023-0544
Source: J Rheumatol - September 15, 2023 Category: Rheumatology Authors: Malki Peskin Marilyn Mostowy Jennifer Velez Megan Perron Jessica Kurian Dawn M Wahezi Source Type: research
